New radiation strategy before brain surgery shows promise
NCT ID NCT04503772
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested giving a precise, high-dose radiation treatment (stereotactic radiosurgery) to brain metastases before surgical removal. The goal was to see if this approach improves local control at 6 months. The trial enrolled 70 adults with up to 4 brain metastases from certain cancers. Participants received radiation followed by surgery within 3 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stereotactic radiosurgery (SRS)
What this could lead to
If successful, this approach could reduce the chance of brain metastases returning after surgery.
What could go wrong
This is a small, non-randomized phase 2 study, so results may not be definitive. Risks include radiation side effects and the possibility that the treatment does not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Grenoble Alpes
Grenoble, 38700, France
-
Centre Hospitalier d'Annecy-Genevois
Metz-Tessy, 74370, France
-
Centre Jean PERRIN
Clermont-Ferrand, Puy-de-Dôme, 63800, France
-
Centre Léon BÉRARD
Lyon, 69373, France
-
Hospices Civils de Lyon
Lyon, 69002, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
-
Institut de cancérologie Strasbourg Europe (ICANS)
Strasbourg, 67000, France
-
Institut de cancérologie de la Loire Lucien Neuwirth
Saint-Priest-en-Jarez, 42270, France